The FDA has granted priority review to Intellia’s biologics license application for lonvo-z and plans to issue a decision by March 10, 2027.
The accelerated approval was based on results from the Phase I/II SOHO-01 trial showing a 75 percent response rate to ...
The Dow Jones Industrial Average rose 1 percent month over month, the Nasdaq rose 4 percent, and the Nasdaq Biotech Index rose 10 percent.
The effort, called SepTech, will begin on Sept. 1 and run through August 2029, and it picks up from an earlier project called ...
The partners will create a secure, Rush-hosted clinical analytics platform to enable Rush researchers to analyze deidentified, longitudinal, and multimodal clinical data.
The bank gave CareDx a price target of $65 per share and BillionToOne of $120 per share, noting their strong positions in non-oncology markets and recent moves into cancer testing.
NEW YORK - Partillion Bioscience announced Wednesday that it received a two-year, $2.1 million research award from the National Institutes of Health Small Business Innovation Research (SBIR) program, ...
The firm will study CT-202 in patients with nextin-4-positive colorectal, urothelial, and triple-negative breast cancers.
The investment bank gave Grail a price target of $105 and Caris, Tempus, and Twist price targets of $28, $70, and $144, respectively.
NEW YORK – Ultima Genomics announced Wednesday that it will collaborate with Nvidia to enable pangenome-aware whole-genome sequencing in its sequencing platform.
NEW YORK – Revvity said on Wednesday that it has entered into a definitive agreement to acquire Human Cell Design (HCD), a French biotechnology company commercializing human cell models and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results